

WORLDWIDE REGISTRATION

Dolutegravir 5 mg Dispersible Tablets

APPROVAL

Argentina	Kenya	Zambia
Australia	Malawi	Zimbabwe
Botswana	Mexico	
Brazil	Namibia	
Canada	Niger	
Chile	Peru'	
China	Singapore	
Colombia	South Africa	
DRC	Switzerland	
Ecuador	Tanzania	
EU	Thailand	
Gabon	Uganda	
Ghana	UK	
Israel	Uruguay	
Kazakhstan	USA	

SUBMISSION

Algeria	Trinidad and Tobago
Burkina Faso	Senegal
Cameroon	UAE
Cote d'Ivoire	Ukraine
Egypt	Uzbekistan
Ethiopia	
Mozambique	
Nigeria	
Turkey	

- ✓ "Approval" means: Marketing Authorisation has been granted by a country or there is no formal regulatory process in place, in the relevant country.
- ✓ "Submission" means: A registration dossier has been submitted to local authority for review in the relevant country. Please note, Submission does not guarantee that a Marketing Authorisation will be granted.
- ✓ Granted Marketing Authorisations may include limitations on the use of the product.

This document was prepared on 07 September 2023 and will be updated on a quarterly basis by ViiV Healthcare. It is made available for information purposes only and ViiV Healthcare accepts no liability arising from the reliance by third parties, on the information provided.